-
November 23, 2018
A sudden influx of new players with standard essential patents into the automotive market is causing conflict between automotive companies and their driverless-car suppliers over who should take a licence in the supply chain
-
.jpg)
November 18, 2018
Managing IP rounds up the latest patent, trade mark and copyright news
-
October 19, 2018
-
June 29, 2018
Managing IP rounds up developments related to the Unified Patent Court and Unitary Patent in June
-
February 05, 2018
Managing IP’s EMEA Awards dinner will be held on March 8 at The Savoy in London. Trophies will be presented to the firms of the year, with winners chosen from these shortlists
-
January 03, 2018
Topics discussed at our recent European Patent Forum USA included the potential timeline for Germany ratifying the UPC, FRAND after Unwired Planet v Huawei, the patentability of computer-implemented inventions at the EPO, patent enforcement strategies in Europe and hot tubbing of experts in the UK
-
December 18, 2017
Associations including CITMA, ECTA, INTA and MARQUES have published position papers discussing IP rights when the UK leaves the EU in March 2019. Managing IP looks at the biggest issues, including registered EU rights, pending applications, exhaustion and representation
-
October 11, 2017
The EPO's Administrative Council has elected António Campinos to succeed Benoit Battistelli as president for a five-year term starting from July 1 2018
-
October 10, 2017
Jesper Kongstad has stepped down as head of Denmark's Patent and Trade Mark Office and joined IP firm Zacco. In this interview, he reflects on recent changes and challenges for national IP offices and the EPO
-
July 24, 2017
UK patent practitioners are in agreement that the UK Supreme Court’s decision in Eli Lilly v Actavis introduced the doctrine of equivalents into UK patent law, but there seems to be some doubt as to whether it also introduced a general doctrine of prosecution history estoppel. Kingsley Egbuonu analyses the decision and its impact on law and practice in the UK
-
July 12, 2017
The UK Supreme Court has ruled that a patentee can argue that the scope of protection afforded by its patent extends beyond the ambit of the claims. In its ruling in Eli Lilly v Actavis, the Court also provided guidance on when reference to EPO prosecution file would be appropriate in interpreting a patent in infringement cases
-
July 06, 2017
Brexit, the UPC, second medical use patents, biologics and digital health were all on the agenda at Managing IP's first European Life Sciences Forum in London
-
June 30, 2017
Legal challenge delays Germany’s UPC Agreement ratification progress; UK government resumes ratification procedure; new start date for the UPC; IP Federation seeks clarity over the case management system; and the latest UPC-related articles on managingip.com include how indirect infringement will be interpreted
-
June 23, 2017
Karolina Wiktorson and Benjamin Hoffmann of Valea review cases relating to the question of contributory infringement, and ask whether the outcome of these may change once the UPC Agreement comes into force
-
June 13, 2017
The Office of the Federal President has agreed to hold off signing the approved laws necessary for the ratification of the UPC Agreement until a court case has been decided
-
May 19, 2017
The Unitary Patent is the biggest development in European patent law in 40 years. Justin Simpson of RWS inovia answers common questions about it
-
May 18, 2017
Patent practitioners will soon be using the UPC case management system. Despite two years of investment in building it, there are lots of questions about how it will work
-
March 30, 2017
A UK IPO statement has confirmed that preparations "remain fully on track" and given more detail on when the last few legislative steps should be expected. This comes a day after Prime Minister Theresa May triggered Article 50 to commence Brexit
-
March 10, 2017
The Global Awards Dinner was held at The Savoy in London on March 9, with 300 guests from 89 firms and 44 countries
-
March 07, 2017
A UK judge has granted a declaration in favour of a number of pharmaceutical companies who are seeking to launch rival products to the world's best-selling drug Humira